© WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editorial Board Chairs: Antonello Mai, Rainer Metternich. Assoc. Editors: David Peralta, Scott Williams (Sr)
Impact Factor: 2.98
ISI Journal Citation Reports © Ranking: 2015: 18/59 (Chemistry Medicinal); 76/253 (Pharmacology & Pharmacy)
Online ISSN: 1860-7187
October 19, 2016
ACT-451840: An Antimalarial Drug with a Novel Mechanism of Action
Malaria remains one of the most significant health burdens in poorer parts of the world. With the recent emergence of initial signs of parasites resistant to artemisinine combination therapy, and in the absence of effective malaria vaccines, the quest for antimalarials with different mechanisms of action has gained increased importance.
Industry–university collaborative efforts led by Christoph Boss (Actelion Pharamceuticals Ltd.) and Sergio Wittlin (Swiss Tropical and Public Health Institute) toward the identification of an antimalarial drug with a novel mechanism of action resulted in the identification of ACT-451840, which was investigated in clinical trials.
Recently Published Articles
- Retro-1 Analogues Differentially Affect Oligonucleotide Delivery and Toxin Trafficking
Bing Yang, Dr. Xin Ming, Hajer Abdelkafi, Valerie Pons, Aurelien Michau, Dr. Daniel Gillet, Dr. Jean-Christophe Cintrat, Dr. Julien Barbier and Dr. Rudy Juliano
Version of Record online: 25 OCT 2016 | DOI: 10.1002/cmdc.201600463
Clarity in Retro-spect: Both oligonucleotides (red ribbons) and toxins (orange squares) enter cells by endocytosis and traffic to early endosomes (EE). Oligos traffic to late endosomes (LE) and thence to lysosomes (LY), where they are degraded. Toxins traffic via the Retromer complex (R) to the trans Golgi (TG) to become active. Retro-1 blocks toxin trafficking and also releases oligos from late endosomes.
- Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases
Dr. Petra Břehová, Dr. Markéta Šmídková, Jan Skácel, Dr. Martin Dračínský, Dr. Helena Mertlíková-Kaiserová, Monica P. Soto Velasquez, Prof. Val J. Watts and Dr. Zlatko Janeba
Version of Record online: 24 OCT 2016 | DOI: 10.1002/cmdc.201600439
The time to ACT is now! Bacterial adenylate cyclases as potential drug targets: This study focused on novel fluorescent acyclic nucleoside phosphonates as potent inhibitors of adenylate cyclase toxin (ACT) from Bordetella pertussis and edema factor (EF) from Bacillus anthracis. The prepared fluorescent compounds are excellent tools to study the molecular interactions between bacterial adenylate cyclases and their potential inhibitors.
- Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
Søren B. van Witteloostuijn, Dr. Søren L. Pedersen and Prof. Knud J. Jensen
Version of Record online: 24 OCT 2016 | DOI: 10.1002/cmdc.201600374
An alternative direction: Despite the commercial success of PEGylation, new strategies for extending the half-lives of biopharmaceuticals are warranted. In this review, we describe the available alternatives with an emphasis on conjugation chemistry, biophysical properties, and biological compatibility.
- Using Chemical Probes to Assess the Feasibility of Targeting SecA for Developing Antimicrobial Agents against Gram-Negative Bacteria
Dr. Jinshan Jin, Dr. Ying-Hsin Hsieh, Dr. Jianmei Cui, Dr. Krishna Damera, Dr. Chaofeng Dai, Dr. Arpana S. Chaudhary, Dr. Hao Zhang, Dr. Hsiuchin Yang, Nannan Cao, Prof. Chun Jiang, Prof. Martti Vaara, Prof. Binghe Wang and Prof. Phang C. Tai
Version of Record online: 18 OCT 2016 | DOI: 10.1002/cmdc.201600421
Broad-spectrum antimicrobials? SecA inhibitors are potent antimicrobials against Gram-positive bacteria. Whether SecA is a valid target against Gram-negative bacteria is an unanswered question. By probing the membrane permeability issue, we found that indeed inhibition of SecA leads to bacteriostatic and bactericidal effects against Gram-negative bacteria. Such effects are not attenuated by the presence of efflux pumps, which are responsible for multidrug resistance. Therefore, SecA is an excellent target for developing broad-spectrum antimicrobials against drug-resistant bacteria.
- Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators
Stefanie Kraege, Sebastian C. Köhler and Prof. Dr. Michael Wiese
Version of Record online: 13 OCT 2016 | DOI: 10.1002/cmdc.201600341
Busted! Acryloylphenylcarboxamides represent a new class of ABCG2 inhibitors. We combined the chalcone moiety with an additional aromatic residue by an amide linker. The position of the aromatic residue as well as that of the dimethoxy substituent on ring B have a large impact on activity. The most promising compound shows high potency and no cytotoxicity.